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http://dx.doi.org/10.1016/j.kjms.201
1607-551X/Copyright ª 2015, KaohsiuAbstract Preliminary evidence suggests that a higher neutrophilelymphocyte ratio (NLR)
may be an indicator of active ulcerative colitis (UC). However, it is not clear whether the
NLR is a useful and simple indicator of clinical activity in UC after adjusting for the other in-
flammatory markers. We designed a retrospective study to evaluate the role of the NLR in esti-
mating disease severity in UC patients. The study consisted of 71 patients with UC and 140 age-
and sex-matched healthy individuals (control group). The NLR, erythrocyte sedimentation
rate, C-reactive protein, and white blood cell count were measured. The NLR values of the
active UC group were elevated compared with those of the patients with inactive UC and
the controls (2.59  1.47, 2.03  1.07, and 1.98  0.85, respectively; pZ 0.005). The receiver
operating characteristic revealed that the optimum NLR cut-off point for active UC was 2.39. A
multivariable logistic analysis showed that of the parameters studied, C-reactive protein was
the only parameter able to significantly discriminate active from inactive UC (B: 0.222;
p Z 0.017; odds ratio: 1.248; 95% confidence interval: 1.041e1.497).
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Ulcerative colitis (UC), a type of inflammatory bowel dis-
ease, is a chronic, idiopathic, relapsing inflammatory con-
dition of the gastrointestinal tract. Histopathological
examinations play a major role in the diagnosis and man-
agement of UC, but they are invasive and costly. In addition
to histological examinations, clinical, laboratory, endo-
scopic, and radiological tests may be needed to confirm a
diagnosis of UC [1].
Systemic inflammatory conditions, such as UC, cause
changes in the levels of circulating white blood cells
(WBCs). It is well known that systemic inflammation induces
an increase in circulating neutrophils that is accompanied
by a relative decrease in the percentages of lymphocyte
[2]. A growing body of evidence suggests that the neu-
trophilelymphocyte ratio (NLR) is a useful biomarker of
systemic inflammation responses [3e6]. Evidence also
suggests that it is a predictor of mortality in patients with
cancer, including colorectal [7,8], biliary tract [9], bladder
[10,11], and breast cancer [12]. The NLR is a cost-effective,
common, and simple biomarker. According to recent
studies, the NLR may be a new promising marker of the
disease severity in UC [13e16]. However, the data on NLR
and its association with other inflammatory serum markers
are not convincing. Therefore, in the present study, we
aimed to determine the relationship between the NLR and
disease activity after adjusting for other inflammatory
serum markers, including C-reactive protein (CRP), the
erythrocyte sedimentation rate (ESR), and WBCs, in pa-
tients with UC.
Methods
This was a retrospective chart review study. The medical
records of 71 patients with UC who were admitted to the
Gaziosmanpas‚a University Hospital, Tokat, Turkey between
December 2010 and January 2013 were included. One
hundred and forty healthy patients without any illness who
were admitted for routine checkups were selected as a
control group. The diagnosis of UC was based on standard
clinical, radiological, laboratory, endoscopic, and histo-
logical findings. The patients’ age, sex, disease duration,
medical history, diabetes mellitus, smoking status, and
laboratory findings, including the neutrophil and lympho-
cyte count, WBCs, CRP, and ESR, were recorded. The NLR
was calculated from the differential count by dividing theTable 1 Demographic characteristics of patients with ulcerativ
Variables Control (n Z 140)
Sex (men/women) 84/56
Age (y) 44.7  12.3
Diabetes mellitus 29 (21)
Smoking 36 (26)
Disease duration (mo)
Data are presented as n (%) or mean  standard deviation.absolute neutrophil count by the absolute lymphocyte
count. All these measured parameters were obtained from
patients with active disease and from those in remission.
Patients who had used corticosteroids within the previ-
ous week or who had hematological or neoplastic disorders,
chronic renal failure, chronic liver or heart diseases, cor-
onary artery disease, connective tissue diseases, or clinical
evidence of active infection were not included in the study.
After obtaining Institutional Review Board approval of the
Gaziosmanpas‚a University Hospital, Tokat, Turkey (#15-
KAEK-168), the study was carried out in accordance with
international Ethical Guidelines and the Declaration of
Helsinki.
The clinical disease activity of UC was evaluated using
the modified Truelove and Witts severity index [17], which
is a composite score incorporating eight variables: stool
frequency, nocturnal diarrhea, visible blood in a stool,
fecal incontinence, abdominal pain, general well-being,
abdominal tenderness, and drugs used to control diar-
rhea. Clinical remission was determined as a score  3 [18].
Statistical analysis
Statistical analysis was performed using the SPSS 15.0 sta-
tistical package (SPSS, Inc., Chicago,. IL, USA). The data
were expressed as means  standard deviation. The Man-
neWhitney U test was used to assess differences in the
demographic parameters, and the KruskaleWallis test was
used to compare the laboratory parameters between the
groups. Spearman’s correlation was used to analyze the
correlation between the parameters. All the p values were
two tailed, and p < 0.05 was considered statistically sig-
nificant. The sensitivity, specificity, and cut-off points were
assessed using a receiver operating characteristic curve
analysis [19]. A multivariate logistic regression model was
used to determine the association of the NLR, CRP, ESR, and
WBC count with active UC.
Results
Seventy-one patients with UC and 140 control individuals
were enrolled in this study. There were 47 men and 24
women in the UC group and 84 men and 56 women in the
control group (pZ 0.453). The demographic information on
the patients and control individuals is summarized in Table 1.
The NLR was increased in the active UC patients
compared with the controls and inactive UC patientse colitis and control participants.
Ulcerative colitis (n Z 71) p
47/24 0.453
46.0  14.7 0.496
13 (18) 0.719
26 (37) 0.111
57.0  24.3
Figure 1. Box-plot representation of neutrophilelymphocyte
ratio in patients with ulcerative colitis and controls. N/L
ratio Z neutrophilelymphocyte ratio.
Table 4 Spearman correlation coefficients between neu-
trophilelymphocyte ratio and other inflammatory markers
in patients with ulcerative colitis.
Patients CRP ESR WBC
rs p rs p rs p
Active UC 0.141 0.246 0.121 0.319 0.360 0.002
Inactive UC 0.020 0.911 0.088 0.468 0.097 0.420
Active and
inactive UC
0.185 0.059 0.170 0.043 0.282 0.001
CRPZ C-reactive protein; ESR Z erythrocyte sedimentation
rate; NLR Z neutrophil lymphocyte ratio; UC Z ulcerative
colitis; WBC Z white blood cells.
Table 3 Results of multivariate logistic regression
analysis.
Variables B p Odds ratio 95% CI
WBC 0.002 0.981 1.002 0.860e1.168
CRP 0.222 0.017 1.248 1.041e1.497
Sedimentation 0.007 0.774 0.993 0.944e1.044
N/L ratio 0.250 0.231 1.283 0.853e1.931
CI Z confidence interval; CRPZ C-reactive protein; N/L
ratio Z neutrophilelymphocyte ratio; WBC Z white blood
cells.
Neutrophil-lymphocyte ratio and ulcerative colitis 587(Figure 1). The NLRs of the control, inactive, and active UC
patients were 1.98  0.85, 2.03  1.07, and 2.59  1.47,
respectively, (pZ 0.005). The other inflammatory markers
(WBCs, CRP, and ESR) were significantly elevated in pa-
tients with active UC compared to those with inactive UC
and the controls (Table 2). A multivariate logistic regression
analysis was used to explore the associations of the NLR,
WBC count, CRP, and ESR with active UC. After adjusting for
these inflammatory markers (WBCs, CRP, and ESR), the odds
ratio of the NLR was 1.283 (95% confidence interval,
0.853e1.931). In the multivariable analysis, CRP was the
only parameter capable of discriminating active from
inactive UC (Table 3).
Spearman’s correlation analysis indicated that there
were significant correlations of NLR with WBC (r Z 0.282,
pZ 0.001) and ESR (rZ 0.170, pZ 0.043) in sum of all UC
patients. There was found a correlation between NLR and
WBC in patients with active UC (r Z 0.360, p Z 0.002);
however, no correlation was found between the NLR and
CRP, ESR, and WBC count in patients with remission. Details
on the correlation between the NLR and the other inflam-
matory parameters in the patients with active disease and
inactive disease and the sum of all UC patients are pre-
sented in Table 4.
The receiver operating characteristic curve analysis
revealed that the cut-off point of the NLR for active UC was
2.39. The overall accuracy of the NLR in the diagnosis of
active UC was 60.9%. The cut-off values of the other UC
activity markers and their sensitivity, specificity, and
overall accuracy are presented in Table 5.Table 2 Comparison of neutrophilelymphocyte ratio and other
colitis patients.
Variables Control (n Z 140) Inact
WBC (mm3) 7638.5  1785.3 731
CRP (mg/dL) 3.85  1.56 4
Sedimentation (mm/h) 10.14  8.62 11
N/L ratio 1.98  0.85 2
Data are presented as mean  standard deviation. Different subscrip
CRPZ C-reactive protein; N/L Z neutrophilelymphocyte ratio; UC ZDiscussion
This study aimed to determine whether the NLR, a novel
inflammatory marker, was an independent, noninvasive
marker of disease activity in UC. Our results demonstrated
that the NLR was higher in patients with active UC
compared with controls and inactive UC patients and that a
cut-off value of 2.39 indicated the presence of active dis-
ease, with a sensitivity of 48.6% and a specificity of 77.5%.
However, after adjusting for the other inflammatory
markers (WBCs, ESR, and CRP), the NLR was not an inde-
pendent marker of the disease severity in UC. Moreover,
there was no significant correlation between the NLR and
the other inflammatory markers, except the WBC count,
with active UC.
UC is a chronic inflammatory disease, which causes
continuous inflammation of the colonic mucosa and affects
the rectum and colon to a variable extent [20]. The clinical
course is marked by exacerbation and remission, whichinflammation markers between active and inactive ulcerative
ive UC (n Z 71) Active UC (n Z 71) p
4.6  2299.6 8903.7  3757.6 0.021
.34  1.82 17.21  15.4 <0.001
.72  10.43 20.94  20.8 0.002
.03  1.07 2.59  1.47 0.005
ts in a row indicate statistically significant difference.
ulcerative colitis; WBC Z white blood cells.
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588 A.K. Demir et al.may occur spontaneously or in response to treatment
changes or other illnesses [21,22]. In clinical practice,
clinical symptoms, the endoscopic appearance, histopa-
thology, biomarkers, and quality of life are used to assess
the disease activity in UC [23]. Endoscopic techniques to
identify the histological persistence of inflammation and
predict relapses are valuable, simple, and practical tools
that can potentially improve the management of patients
with UC [24]. However, endoscopy is not able to predict
relapses in patients with inactive UC. Compared with
endoscopy, some noninvasive biomarkers may be more
useful in predicting relapses in UC patients in remission
[25,26].
The WBC count, CRP, and ESR are the most commonly
used inflammatory indices in routine clinical practice for
determining active UC [27]. However, they do not
adequately reflect disease activity due to their low sensi-
tivity and specificity for intestinal inflammation [28,29].
Therefore, none of these simple serum markers alone is
sufficient as an activity indicator for UC. Previous studies
demonstrated that CRP and ESRs are more meaningful pa-
rameters than WBC counts for determining the disease ac-
tivity [14,27,29]. Osada et al [27] reported that CRP, ESRs,
and WBC counts were correlated with the sum of endo-
scopic and histological scores. They also found that CRP and
the ESR were well correlated with the activity of proximal
colonic lesions but not with that of distal lesions. The use of
CRP and other laboratory markers should be viewed as an
addition to clinical observations and a physical examination
rather than a replacement [29]. The combined use of these
markers with a colonoscopy will enhance their importance
in determining UC activity.
Recent studies demonstrated that the NLR was higher in
patients with active UC [13,14]. The retrospective study
[13], which included UC patients with active disease or
patients in remission, found that an optimum cut-off value
of 2.16 indicated the presence of active disease, with a
sensitivity of 81.8% and a specificity of 80.5%. The other
study [14], which included 40 patients with UC with active
disease or in remission, reported that the cut-off point for
active UC was 2.47, with a sensitivity of 53.9% and a
specificity of 63.2%. In these two studies, the sensitivity and
specificity values were different. Interestingly, the speci-
ficity and sensitivity values in one of the studies [14] were
low, despite the high optimal cut-off value. The present
study consisted of 71 UC patients with active and inactive
disease and 140 control patients. We found that the opti-
mum cut-off value for active UC was 2.39, with a sensitivity
of 48.6% and a specificity of 77.5%. The optimum NLR cut-
off point for active UC was in the range of 2.16e3.1 in
different studies [13e16]. Our results were close to those
reported by C¸elikbilek et al [14]. In the present study, we
also evaluated the statistically significant parameters in a
multivariable analysis. The results of that analysis showed
that CRP was the only statistically significant parameter
capable of discriminating active UC from inactive disease in
those in remission. Therefore, the NLR, with its low sensi-
tivity and specificity rates, was not as effective as CRP for
determining active UC. Spearman’s correlation analysis
demonstrated that there was no significant correlation
between the NLR and the other laboratory markers, except
the WBC count, in active UC.
Neutrophil-lymphocyte ratio and ulcerative colitis 589This study has several limitations. Firstly, it was con-
ducted among inpatients at our hospital in northern Turkey.
Therefore, the results may not be representative of the
general characteristics of patients with UC in Turkey, and
the findings cannot be generalized countrywide. Secondly,
the study consisted of a relatively small sample size, and it
had a cross-sectional design. Prospective studies, including
a larger sample size, are needed to provide more useful
information on this subject. Thirdly, our study was not
designed to explain the observed increases in the NLR in
patients with active UC. Finally, other factors, such as
corticosteroid dosages and use of immunosuppressive
agents, which may affect the level of inflammatory markers
which were not evaluated in the present study.
Our study demonstrated that the NLR was elevated in
patients with active UC. However, after adjusting for other
statistically significant laboratory markers, including CRP,
ESRs, and WBC counts, the NLR was not a useful predictor
of active disease. Moreover, the NLR showed no correlation
with other laboratory markers, including CRP and the ESR,
in patients with active UC. Therefore, although the NLR is
an inexpensive and accessible inflammatory laboratory
marker, it is not an independent risk factor for indicating
the disease activity in UC.References
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